Open AccessSoluble endothelium‐associated adhesion molecules in patients with Graves' disease
Author(s) -
WENISCH C.,
MYSKIW D.,
PARSCHALK B.,
HARTMANN T.,
DAM K.,
GRANINGER W.
Publication year - 1994
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1994.tb06132.x
Subject(s) - medicine , graves' disease , endocrinology , thyroid peroxidase , cell adhesion molecule , endothelium , thyroglobulin , intercellular adhesion molecule 1 , soluble cell adhesion molecules , thyroid , antibody , adhesion , immunology , cell adhesion , inflammation , chemistry , organic chemistry
SUMMARY The targeting and recruitment of inflammatory cells to vascular endothelium in Graves' disease (GD) is mediated by intercellular adhesion molecule‐1 (ICAM‐1), endothelial leucocyte adhesion molecule‐1 (ELAM‐1), and vascular cell adhesion molecule‐1 (VCAM‐1). We have studied serum levels of soluble ICAM‐1 (sICAM‐1), soluble ELAM‐1 (sELAM‐1), and soluble VCAM‐1 (sVCAM‐1) in patients with GD ( n = 21) and in patients with iodine‐deficient goitre (IDG) ( n = 23). The serum levels of sICAM‐1 were markedly elevated in patients with GD before treatment with thiamazole (median 560 ng/ml versus 185 ng/ml in patients with IDG). In addition, elevated serum concentrations of sELAM‐1 (median 85 ng/ml versus 33 ng/ml, respectively) and sVCAM‐1 (median 42 ng/ml versus 15 ng/ml, respectively) were observed in patients with GD ( P < 001 for all). The serum levels of sELAM‐1 and sVCAM‐1 dropped significantly after initiation of therapy and were within the normal range after 4, and 8 weeks of therapy, respectively. Serum levels of sICAM‐1 were elevated even after 8 weeks of therapy. Serum levels of sVACM‐1 and sICAM‐1 correlated with the serum concentrations of anti‐thyroid‐stimulating hormone (TSH)‐receptor antibodies (TSHR‐R) ( n = 21; r = 0929 and r = 0810, respectively) and anti‐thyroid peroxidase antibodies (TPO‐Ab) ( n = 21; t =0‐673 and r = 0‐750, respectively). However, no correlation between sELAM‐1 and TPO‐Ab, TSHR‐R, and anti‐thyroglobulin antibodies (Tg‐Ab), respectively, could be found. In addition to thyroid hormones and autoantibodies, serum concentrations of sELAM‐1 and sVCAM‐1, but not sICAM‐1, could be useful as clinical markers for disease activity.